Page last updated: 2024-11-06

piritrexim

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Piritrexim is a potent and selective inhibitor of the enzyme thymidylate synthase (TS). TS is a crucial enzyme involved in the synthesis of thymidine, a building block for DNA. By inhibiting TS, piritrexim prevents DNA replication and cell proliferation, making it a potential anticancer agent. Piritrexim has been studied extensively in preclinical models of cancer, demonstrating significant antitumor activity against various tumor types. Its high selectivity for TS over other enzymes, combined with its oral bioavailability, makes it a promising candidate for cancer therapy. However, piritrexim has not yet been approved for clinical use due to its toxicity profile. Ongoing research focuses on improving its therapeutic index and exploring its potential in combination therapies to enhance its efficacy.'

piritrexim: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54369
CHEMBL ID7492
SCHEMBL ID8124
MeSH IDM0082845

Synonyms (44)

Synonym
brn 5768301
piritrexim [inn]
piritrexima [spanish]
piritreximum [latin]
pyrido(2,3-d)pyrimidine-2,4-diamine, 6-((2,5-dimethoxyphenyl)methyl)-5-methyl-
piritrexime [french]
2,4-diamino-5-methyl-6-(2,5-dimethoxybenzyl)pyrido(2,3-d)pyrimidine
6-((2,5-dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine
2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-d)pyrimidine
301u74
bw-301u
piritrexim
6-[(2,5-dimethoxyphenyl)methyl]-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine
6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine
6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine mono(2-hydroxyethanesulfonate)
bw 301u
MXA ,
DB03695
[2-amino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidin-4-yl]amine;2-hydroxyethanesulfonic acid
bdbm18224
6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
chembl7492 ,
72732-56-0
6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine
TCMDC-137235 ,
piritrexime
piritrexima
mk2a783zut ,
unii-mk2a783zut
piritreximum
1U71
6-[(2,5-dimethoxyphenyl)methyl]-5-methylpyrido[3,2-e]pyrimidine-2,4-diamine
gtpl7414
SCHEMBL8124
piritrexim [mi]
piritrexim [who-dd]
DTXSID20223032
AKOS016845844
2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine
Q27088402
bw 301u; nsc 351521
BCP29680
bw 301u;bw301u
A902506

Research Excerpts

Overview

Piritrexim (PTX) is a new antifolate that has shown activity in methotrexate-resistant tumors. It is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated.

ExcerptReferenceRelevance
"Piritrexim is a new antifolate that has shown activity in methotrexate-resistant tumors. "( Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Binger, K; Feierabend, C; Liu, G; Marnocha, R; Thomas, JP; Volkman, J; Wilding, G, 2003
)
2.05
"Piritrexim is a lipid-soluble drug which is as effective an inhibitor of dihydrofolate reductase as methotrexate. "( A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
Bedford, P; Bleehen, NM; Nethersell, AB; Newman, HV; Rampling, RP; Ramsay, JR; Roberts, JT, 1995
)
2.04
"Piritrexim isethionate is a lipid-soluble dihydrofolate reductase inhibitor which cannot form polyglutamates, and may be as effective as methotrexate in the treatment of psoriasis."( A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
Baker, H; Cunliffe, WJ; Klaber, MR; Layton, AM; Manna, VK; Perkins, W; Saihan, EM; Tidman, MJ; Vestey, JP; Williams, RE, 1993
)
1.24
"Piritrexim is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit dihydrofolate reductase. "( A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
Crawshaw, A; de Vries, EG; Dennis, I; Dobbs, HJ; Gietema, JA; Mulder, NH; Scott, JE; Sleijfer, DT; Willemse, PH; Workman, P, 1993
)
1.99
"Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. "( Oral piritrexim, an effective treatment for metastatic urothelial cancer.
de Wit, R; Kaye, SB; Roberts, JT; Scott, J; Stoter, G; Verweij, J, 1993
)
2.24
"Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. "( A phase II study of piritrexim in patients with advanced squamous head and neck cancer.
Clendeninn, NJ; Havlin, K; Huang, AT; Jones, SE; Keegan, P; Killion, K; Mennel, R; Spaulding, MB; Uen, WC, 1992
)
2.05
"Piritrexim isethionate is a lipid-soluble antifolate that has a mechanism of action similar to that of methotrexate."( Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist.
Benik, K; Guzzo, C; Johnson, J; Lazarus, G; Weinstein, G, 1991
)
1.3
"Piritrexim (PTX) is a second-generation, lipid-soluble inhibitor of dihydrofolate reductase (DHFR). "( Initial clinical studies of piritrexim.
Brenckman, WD; Clendeninn, NJ; Currie, V; Laszlo, J; Morgan, E; Williams, T; Young, C, 1987
)
2.01

Effects

ExcerptReferenceRelevance
"Piritrexim has minimal activity in patients with previously treated transitional cell carcinoma of the bladder, regardless of prior exposure to methotrexate, and further evaluation of this compound in this clinical setting is not warranted."( Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group.
Dreicer, R; Graham, D; Manola, J; Roth, BJ; Wilding, G, 2002
)
3.2

Actions

ExcerptReferenceRelevance
"Piritrexim was able to inhibit replication of T."( Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.
Allegra, CJ; Chabner, BA; Drake, JC; Kovacs, JA; Masur, H; Parrillo, JE; Swan, JC, 1988
)
1.24

Toxicity

ExcerptReferenceRelevance
" However, the toxic effects of piritrexim and trimetrexate suggest that dihydrofolate reductase (DHFR) activity is essential for the parasite, most probably because of the role of this enzyme in the synthesis of thymidine nucleotides via thymidylate synthase."( The toxicity of antifolates in Babesia bovis.
Bagnara, AS; Nott, SE, 1993
)
0.57

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic monitoring was performed in 15 of the 18 children."( Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
Adamson, PC; Arndt, C; Aronson, L; Balis, FM; Clendeninn, NJ; Gillespie, A; Miser, J; Penta, JS; Poplack, DG; Wells, RJ, 1992
)
0.51
" Pharmacokinetic monitoring was performed at steady state during the first course."( Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
Adamson, PC; Balis, FM; Bleyer, WA; Clendeninn, NJ; Gillespie, A; Miser, J; Penta, JS; Poplack, DG; Wells, RJ; Williams, TE, 1990
)
0.53
" Pharmacokinetic analysis of piritrexim in three patients during the first treatment cycle, revealed peak levels 1 to 2 h after an oral dose, with a trend towards a higher peak plasma levels and AUCs on the fourth dosing day compared with the first dosing day."( A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
Crawshaw, A; de Vries, EG; Dennis, I; Dobbs, HJ; Gietema, JA; Mulder, NH; Scott, JE; Sleijfer, DT; Willemse, PH; Workman, P, 1993
)
0.83

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability of unchanged drug was less than 5%."( The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration.
Crouch, RC; Deangelis, DV; Shockcor, JP; Sigel, CW; Woolley, JL,
)
0.4
" Mean systemic bioavailability after oral administration was 75 +/- 56%."( A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
Blum, MR; Clendeninn, NJ; Liao, SH; Sarosy, GA; Shenkenberg, TD; Von Hoff, DD; Weiss, GR; Williams, T; Woolley, JL, 1989
)
0.5
" Bioavailability after oral dosing is approximately 75%."( Oral piritrexim, an effective treatment for metastatic urothelial cancer.
de Wit, R; Kaye, SB; Roberts, JT; Scott, J; Stoter, G; Verweij, J, 1993
)
0.8

Dosage Studied

ExcerptRelevanceReference
" A number of different regimens were tested, including daily dosing for 21 days followed by 7 days of no drug therapy; continuous dosing; and daily dosing for 5 of 7 days for 3 consecutive weeks followed by a week of rest."( Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
Benedetto, P; Clendeninn, NJ; Collier, M; Feun, LG; Hanlon, J; Liao, SH; Richman, S; Savaraj, N; Sridhar, KS, 1991
)
0.62
" Based on experience gained from oncologic trials, each patient received a twice-daily dosage for 5 consecutive days every 2 weeks."( Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist.
Benik, K; Guzzo, C; Johnson, J; Lazarus, G; Weinstein, G, 1991
)
0.58
" One patient at each dosage level received an initial weekly dose of PTX in oral form accompanied by pharmacokinetic blood sampling after the oral dose and also after a subsequent intravenous dose."( A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
Blum, MR; Clendeninn, NJ; Liao, SH; Sarosy, GA; Shenkenberg, TD; Von Hoff, DD; Weiss, GR; Williams, T; Woolley, JL, 1989
)
0.5
" Pharmacokinetic analysis of piritrexim in three patients during the first treatment cycle, revealed peak levels 1 to 2 h after an oral dose, with a trend towards a higher peak plasma levels and AUCs on the fourth dosing day compared with the first dosing day."( A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
Crawshaw, A; de Vries, EG; Dennis, I; Dobbs, HJ; Gietema, JA; Mulder, NH; Scott, JE; Sleijfer, DT; Willemse, PH; Workman, P, 1993
)
0.83
" Bioavailability after oral dosing is approximately 75%."( Oral piritrexim, an effective treatment for metastatic urothelial cancer.
de Wit, R; Kaye, SB; Roberts, JT; Scott, J; Stoter, G; Verweij, J, 1993
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (16)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductase Mycobacterium aviumIC50 (µMol)0.00060.00060.17161.5000AID240892; AID57477; AID57956; AID58090; AID58091
Dihydrofolate reductaseHomo sapiens (human)IC50 (µMol)0.00240.00060.87267.3000AID1392483; AID1591492; AID1591497; AID56807; AID747614
Dihydrofolate reductaseHomo sapiens (human)Ki0.02370.00000.37564.9000AID219254; AID57133; AID57140
Dihydrofolate reductaseLacticaseibacillus caseiIC50 (µMol)0.00150.00130.26964.9000AID55724
Dihydrofolate reductaseSaccharomyces cerevisiae S288CIC50 (µMol)0.03100.03100.03650.0420AID55696
Dihydrofolate reductaseEscherichia coli K-12IC50 (µMol)0.02440.00150.55126.8000AID55683; AID55714; AID55859; AID56347; AID57630
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)IC50 (µMol)0.01100.00231.21555.0000AID56188
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.03800.00040.908610.0000AID55859
Dihydrofolate reductasePneumocystis cariniiIC50 (µMol)0.02570.00060.54766.2000AID1198821; AID1797706; AID240926; AID390567; AID55687; AID55689; AID55698; AID55699; AID55701; AID55703; AID55705; AID55820; AID55823; AID55825; AID55827; AID55830; AID55832; AID55833; AID55835; AID55836; AID55838; AID55839; AID55840; AID55841; AID55843; AID55844; AID55856; AID57072; AID57628; AID747610
Dihydrofolate reductasePneumocystis cariniiKi0.00010.00000.04680.1520AID55851
Aromatic-L-amino-acid decarboxylaseHomo sapiens (human)IC50 (µMol)0.00060.00060.00060.0006AID57477
Dihydrofolate reductaseCandida albicansIC50 (µMol)0.04000.00220.91875.0000AID57074
Dihydrofolate reductaseCandida albicansKi0.00190.00190.00190.0019AID57076
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)0.01400.00010.444410.0000AID56182; AID56188
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00910.00040.615610.0000AID57971; AID57989
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00430.00020.660310.0000AID240835
Bifunctional dihydrofolate reductase-thymidylate synthaseToxoplasma gondiiIC50 (µMol)0.01340.00061.042810.0000AID1198822; AID1797706; AID240835; AID55711; AID56162; AID56165; AID56167; AID56169; AID56172; AID56174; AID56176; AID56178; AID56180; AID56182; AID56183; AID56186; AID56188; AID56310; AID56314; AID56317; AID56318; AID56319; AID56321; AID56324; AID56325; AID56326; AID56330; AID56346
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00060.35076.2000AID1797706; AID240573; AID390569; AID57796; AID57797; AID57799; AID57804; AID57811; AID57812; AID57819; AID57820; AID57824; AID57825; AID57960; AID57961; AID57965; AID57968; AID57969; AID57971; AID57972; AID57976; AID57977; AID57978; AID57979; AID57980; AID57982; AID57984; AID57988; AID57989; AID57990; AID747611
Dihydrofolate reductase Pneumocystis jiroveciiIC50 (µMol)0.04100.04100.06650.0920AID1392482
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
tetrahydrobiopterin biosynthetic processDihydrofolate reductaseHomo sapiens (human)
one-carbon metabolic processDihydrofolate reductaseHomo sapiens (human)
negative regulation of translationDihydrofolate reductaseHomo sapiens (human)
axon regenerationDihydrofolate reductaseHomo sapiens (human)
response to methotrexateDihydrofolate reductaseHomo sapiens (human)
dihydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate metabolic processDihydrofolate reductaseHomo sapiens (human)
tetrahydrofolate biosynthetic processDihydrofolate reductaseHomo sapiens (human)
folic acid metabolic processDihydrofolate reductaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityDihydrofolate reductaseHomo sapiens (human)
regulation of removal of superoxide radicalsDihydrofolate reductaseHomo sapiens (human)
10-formyltetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to xenobiotic stimulusDihydrofolate reductaseEscherichia coli K-12
folic acid biosynthetic processDihydrofolate reductaseEscherichia coli K-12
one-carbon metabolic processDihydrofolate reductaseEscherichia coli K-12
response to methotrexateDihydrofolate reductaseEscherichia coli K-12
tetrahydrofolate biosynthetic processDihydrofolate reductaseEscherichia coli K-12
response to antibioticDihydrofolate reductaseEscherichia coli K-12
dihydrofolate metabolic processDihydrofolate reductaseEscherichia coli K-12
folic acid metabolic processDihydrofolate reductaseEscherichia coli K-12
kidney developmentAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
amino acid metabolic processAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
response to toxic substanceAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
gene expressionAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
carboxylic acid metabolic processAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
dopamine biosynthetic processAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
serotonin biosynthetic processAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
catecholamine metabolic processAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
mRNA regulatory element binding translation repressor activityDihydrofolate reductaseHomo sapiens (human)
mRNA bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseHomo sapiens (human)
folic acid bindingDihydrofolate reductaseHomo sapiens (human)
NADPH bindingDihydrofolate reductaseHomo sapiens (human)
sequence-specific mRNA bindingDihydrofolate reductaseHomo sapiens (human)
NADP bindingDihydrofolate reductaseHomo sapiens (human)
dihydrofolate reductase activityDihydrofolate reductaseEscherichia coli K-12
protein bindingDihydrofolate reductaseEscherichia coli K-12
folic acid bindingDihydrofolate reductaseEscherichia coli K-12
oxidoreductase activityDihydrofolate reductaseEscherichia coli K-12
NADP bindingDihydrofolate reductaseEscherichia coli K-12
methotrexate bindingDihydrofolate reductaseEscherichia coli K-12
dihydrofolic acid bindingDihydrofolate reductaseEscherichia coli K-12
NADP+ bindingDihydrofolate reductaseEscherichia coli K-12
NADPH bindingDihydrofolate reductaseEscherichia coli K-12
aromatic-L-amino-acid decarboxylase activityAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
protein bindingAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
enzyme bindingAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
pyridoxal phosphate bindingAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
5-hydroxy-L-tryptophan decarboxylase activityAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
L-dopa decarboxylase activityAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseHomo sapiens (human)
mitochondrionDihydrofolate reductaseHomo sapiens (human)
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolDihydrofolate reductaseEscherichia coli K-12
cytosolAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
extracellular exosomeAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
cytoplasmAromatic-L-amino-acid decarboxylaseHomo sapiens (human)
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (249)

Assay IDTitleYearJournalArticle
AID56176Concentration inhibiting Toxoplasma gondii dihydrofolate reductase1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID55833Inhibitory activity against Pneumocystis carinii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID55944Cytotoxic activity was evaluated against Daoy tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57989The ability to inhibit rat liver Dihydrofolate reductase was tested1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID57956Inhibition of Dihydrohydrofolate reductase(DHFR) of Mycobacterium avium2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID55843The ability to inhibit Pneumocystis carinii Dihydrofolate reductase was tested1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID234269Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID57468Inhibitory activity against Dihydrofolate reductase isolated from murine L5178Y tumor cells sensitive to methotrexate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID57796Inhibition of partially purified dihydrofolate reductase (DHFR) from rat liver2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID58153Selective index against dihydrofolate reductase of Rat liver and dihydrofolate reductase of Pneumocystis carinii2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID214045Cytotoxic activity was evaluated against U87MG tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID234733Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID57979Inhibitory concentration against dihydrofolate reductase DHFR from rat liver.2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID233680Selectivity ratio of rat liver(rl) / Pneumocystis carinii (pc)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID232061Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Toxoplasma gondii DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID154146Cytotoxic activity was evaluated against P388D1/ADR cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID234748Selectivity ratio of Ki value against mutant DHFR and Wild-type DHFR.1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID235298Ratio of DHFR inhibition of rat liver to that of Mycobacterium avium2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID232631Ratio of inhibitory activity against dihydrofolate reductase of rat liver to pneumocystis carinii2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID233636Ratio of inhibitory concentration of rat liver and Pneumocystis carinii DHFR.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID235849Selectivity ratio is the ratio between the IC50 values of rat liver and Pneumocystis carinii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID56172Inhibitory activity against Toxoplasma gondii dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID57630Inhibition of dihydrofolate reductase from pneumocystis carinii.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID233681Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
AID1392484Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID390569Inhibition of rat liver dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID57825Inhibition of Dihydrofolate Reductase of Rat Liver.1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
AID747611Inhibition of rat liver DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID235851Selectivity ratio is the ratio between the IC50 values of rat liver and Toxoplasma gondii1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID747609Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID56807In vitro inhibition of human dihydrofolate reductase1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID154150Cytotoxic Activity was evaluated against P388D1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID94710Cytotoxic activity was evaluated against L tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID234270Ratio of IC50 rat liver DHFR vs IC50 of Toxoplasma gondii DHFR1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID57814Inhibition against Dihydrofolate reductase in rat liver1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID98036Cytotoxic activity against the L1210 cell cultures1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
AID101912Cytotoxic activity was evaluated against MCF-7/ADR+Reserpine cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55841Inhibitory concentration against dihydrofolate reductase dihydrofolate reductase from Pneumocystis carinii.2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID56162Inhibition of partially purified dihydrofolate reductase (DHFR) from Toxoplasma gondii (Tg)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID56188Inhibition of Dihydrofolate Reductase of Toxoplasma gondii.1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
AID57982Inhibition of rat liver dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID55827Inhibitory activity against dihydrofolate reductase (DHFR) from Pneumocystis carinii1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID8659Cytotoxic activity evaluated against A549 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID58090Inhibitory concentration against Mycobacterium avium dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID57812Inhibitory concentration against rat liver dihydrofolate reductase (DHFR)1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID747613Inhibition of Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID214392Cytotoxic activity was evaluated against U373MG tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID240926Inhibitory concentration against Pneumocystis carinii DHFR2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID235862IC50(rlDHFR)/IC50(tgDHFR) Ratio of the compound2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID55701Inhibition of Pneumocystis carinii dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID56178Inhibition of Toxoplasma gondii dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID58149Ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Toxoplasma gondii(tg)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID235504Selectivity ratio was measured as IC50 of rlDHFR/IC50 tgDHFR1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID57467Inhibitory activity against Dihydrofolate reductase isolated from murine L5178Y tumor cells resistant to methotrexate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID1392483Inhibition of human recombinant DHFR expressed in Escherichia coli Rosetta Gami B (DE3) competent cells using DHFA as substrate and NADPH2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
AID138280Effect on life span of mice with intraperitoneally implanted P388/ADR Leukemic cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID48922Minimum inhibitory concentration required to inhibit Candida albicans (in vitro)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID747614Inhibition of human recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID56169Inhibition of dihydrofolate reductase (DHFR) from Toxoplasma gondii(tg)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID219254Inhibitory activity against Wild-type human DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID56174Compound was tested for inhibition activity against Toxoplasma gondii (Toxoplasma gondii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID235861IC50(rlDHFR)/IC50(pcDHFR) Ratio of the compound2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID56347Inhibition of dihydrofolate reductase in Toxoplasma gondii.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID233682Selectivity ratio of rat liver(rl) / Toxoplasma gondii (tg)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID56321Inhibitory concentration against Toxoplasma gondii Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID58148Ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Pneumocystis carinii(pc)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID94508Cytotoxic activity was evaluated against KBV-1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID100309Cross resistance to the compound expressed as log of ratio of molar concentration of drug inducing 50% inhibition of growth in murine leukemia L1210/R71 and L1210/0 cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID55844Inhibition of dihydrofolate reductase (DHFR) from Pneumocystis carinii(pc)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID234735Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID232060Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Pneumocystis carinii DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID248511Concentration causing inhibition of CCRF-CEM human leukemic lymphoblasts growth in a 72 hr culture2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID138276Effect on life span of mice with intracranially implanted P388 Leukemic cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56326Inhibitory concentration against dihydrofolate reductase of Toxoplasma gondii2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID57990Inhibition of dihydrofolate reductase (DHFR) from rat liver (rl)1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
AID65357Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID1591492Inhibition of recombinant human DHFR assessed as reduction in consumption of NADPH using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID244389Selectivity index measured as IC50(Rat)/IC50(Pneumocystis carinii)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID216019Cytotoxic Activity was evaluated against Vero tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55836Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID56330The ability to inhibit Toxoplasma gondii Dihydrofolate reductase was tested1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID56324Inhibitory concentration against Toxoplasma gondii dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID65359Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Quantitative structure-activity relationship of antifolate inhibition of bacteria cell cultures resistant and sensitive to methotrexate.
AID57477Concentration required to inhibit the Mycobacterium avium Dihydrofolate reductase by 50% was determined; Range: 0.53-0.702004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID235657Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Mycobacterium avium DHFR; Range: 4.1-7.22004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID94350Cytotoxic activity was evaluated against KB3-1 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID1591496Inhibition of Pneumocystis jirovecii DHFR expressed in Escherichia coli Rosetta-gami B (DE3) assessed as reduction in consumption of NADPH using 9 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID57824Inhibition Dihydrohydrofolate reductase(DHFR) of rat liver2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID57799Concentration inhibiting rat liver dihydrofolate reductase. 1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID55823Inhibition of Dihydrohydrofolate reductase(DHFR) of Pneumocystis carinii2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID1198822Inhibition of Toxoplasma gondii DHFR by spectrophotometric assay2015European journal of medicinal chemistry, May-05, Volume: 95Recent advances in the chemistry and biology of pyridopyrimidines.
AID1591495Selectivity ratio of IC50 for inhibition of recombinant human DHFR using 18 uM DHFA as substrate to IC50 for inhibition of Pneumocystis jirovecii DHFR using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID57968Inhibitory activity against rat liver dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID57960Inhibition of dihydrofolate reductase from rat liver.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID55840Inhibitory concentration against Pneumocystis carinii dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID57819Inhibition of Dihydrofolate reductase (DHFR) of in rat liver1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID57074Inhibition of dihydrofolate reductase in Candida albicans (in vitro).1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines.
AID57140Inhibitory activity against Leu22-Phe mutant human Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID58152Selective index against dihydrofolate reductase of Rat liver to dihydrofolate reductase of M. avium; ND is not determined2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID56325Inhibitory concentration against dihydrofolate reductase DHFR from Toxoplasma gondii2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii.
AID55839Inhibitory concentration against Pneumocystis carinii Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID55581Cytotoxic Activity was evaluated against D54 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID58157Selective index for Dihydrofolate reductase was determined by IC50(rat liver) / IC50(Toxoplasma gondii)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID235896Selectivity Index is the ratio of the inhibitory concentrations against rat liver (RL) DHFR and Toxoplasma gondii (Tg) DHFR.1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID57076Inhibition of Dihydrofolate reductase enzyme from Candida albicans1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID233406Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID55698Compound was tested for inhibition activity against pneumocystis carinii (Pneumocystis carinii) Dihydrofolate reductase1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID202616Cytotoxic activity against the S180 cell cultures1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
AID55687Inhibition of Pneumocystis carinii dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID15621Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55825Inhibition of Dihydrofolate Reductase of Pneumocystis carinii.1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
AID78832Cytotoxic Activity was evaluated against HCT-8 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57797Compound was tested for inhibition activity against rat liver lipophilic Dihydrofolate reductase (DHFR).1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID55699Concentration inhibiting Pneumocystis carinii dihydrofolate reductase1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
2,4-Diaminopyrido[3,2-d]pyrimidine inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii.
AID244390Selectivity index measured as IC50(Rat)/IC50(Toxoplasma gondii)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID55714Inhibition of dihydrofolate reductase from Toxoplasma gondii.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID233637Ratio of inhibitory concentration of rat liver and Toxoplasma gondii DHFR1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID747610Inhibition of Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID55705Inhibition of Dihydrofolate reductase of Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID58154Selective index against dihydrofolate reductase of Rat liver and Toxoplasma gondii2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID233284Relative binding affinity for rat liver and Pneumocystis carinii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID55703Inhibition against Dihydrofolate reductase in Pneumocystis carinii1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID57980Inhibitory concentration against dihydrofolate reductase of rat liver2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID57977Inhibitory concentration against Dihydrofolate reductase from Rat liver (rl)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID57804Concentration required to inhibit the rat liver Dihydrofolate reductase by 50% was determined; Range: 2.9-3.92004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID233287Selectivity ratio is IC50 of rat liver DHFR to that of Toxoplasma gondii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID235300Ratio of DHFR inhibition of rat liver to that of Toxoplasma gondii2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID57972Inhibitory activity against rat liver Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID235895Selectivity Index is the ratio of the inhibitory concentrations against rat liver (RL) DHFR and Pneumocystis carinii (Pc) DHFR.1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.
AID58156Relative affinity for Dihydrofolate reductase from rat liver and Pneumocystis carinii2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID94507Cytotoxic activity was evaluated against KBV-1 cells in presence of reserpine1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID152988Cytotoxic activity was evaluated against P388/ADR + reserpine cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56165Inhibition of Toxoplasma gondii dihydrofolate reductase1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
AID1591498Selectivity ratio of IC50 for inhibition of recombinant human DHFR using 9 uM DHFA as substrate to IC50 for inhibition of Pneumocystis jirovecii DHFR using 9 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID240892Inhibitory concentration against Mycobacterium avium DHFR2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID56183Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID232059Selectivity index was determined as ratio of IC50 against rat DHFR to that of IC50 against Mycobacterium avium DHFR2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID240573Inhibitory concentration against rat DHFR2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID55711Concentration required to inhibit the Toxoplasma gondii Dihydrofolate reductase by 50% was determined; Range: 4.0-4.62004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID229684Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID240835Inhibitory concentration against Toxoplasma gondii DHFR2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID58155Relative affinity for Dihydrofolate reductase of rat liver and Mycobacterium avium2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID48772Minimum inhibitory concentration evaluated against Candida albicans1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID233683Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases.
AID57820Inhibitory activity against Dihydrofolate reductase from rat liver1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID57952Ability to inhibit partially purified dihydrofolate reductase (DHFR) from Mycobacterium avium.2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID57984Inhibition of rat liver Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID57988Inhibition of rat liver dihydrofolate reductase.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID15619Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID227227Selectivity ratio measured as the IC50 ratio of rlDHFR to the IC50 pcDHFR1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID101911Cytotoxic activity was evaluated against MCF-7/ADR cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID233115Ratio of the IC50 against rat liver DHFR and Toxoplasma gondii DHFR (IC50rl/IC50tg)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID55830Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID55696Inhibitory activity against Pneumocystis carinii dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID231132Ratio of the inhibitory concentrations against rat liver DHFR and Toxoplasma gondii DHFR.1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID231131Ratio of the inhibitory concentrations against rat liver DHFR and Pneumocystis carinii DHFR1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID1392482Inhibition of Pneumocystis jirovecii recombinant DHFR expressed in Escherichia coli Rosetta Gami B (DE3) competent cells using DHFA as substrate and NADPH2018Bioorganic & medicinal chemistry, 05-15, Volume: 26, Issue:9
Targeting species specific amino acid residues: Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors and potential anti-opportunistic infection agents.
AID57133Inhibition of human recombinant Dihydrofolate reductase enzyme1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID56182Inhibition of Dihydrofolate reductase of Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID55689Inhibition of Pneumocystis carinii (pc) Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID233286Relative binding affinity to rat liver and Toxoplasma gondii DHFR.1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID56310Inhibitory activity against dihydrofolate reductase (DHFR) from Toxoplasma gondii1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID57978Inhibitory concentration against Rat liver Dihydrofolate reductase1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID56319Inhibitory concentration against Dihydrofolate reductase from Toxoplasma gondii (tg)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID56346Inhibitory activity against Toxoplasma gondii DHFR*2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID57072Inhibitory concentration against dihydrofolate reductace enzyme of Pneumocystis carinii2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID56167Inhibition of Toxoplasma gondii (tc) Dihydrofolate reductase1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID210619Inhibition of Toxoplasma gondii cell growth1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID58091Inhibitory concentration against dihydrofolate reductase of Mycobacterium avium2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID101910Cytotoxic activity was evaluated against MCF-7 cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID747608Inhibition of Mycobacterium avium DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID56180Inhibition against Dihydrofolate reductase in Toxoplasma gondii1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Effect of N9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID217943Cytotoxic activity against the Walker 256 carcinosarcoma in rats1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
AID56318Inhibitory activity against Toxoplasma gondii dihydrofolate reductase1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
AID138278Effect on life span of mice with intraperitoneally implanted P388 Leukemic cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID1591491Inhibition of Pneumocystis jirovecii DHFR expressed in Escherichia coli Rosetta-gami B (DE3) assessed as reduction in consumption of NADPH using 18 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID227228Selectivity ratio measured as the IC50 ratio of rlDHFR to the IC50 tgDHFR.1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID57971Inhibitory activity against rat dihydrofolate reductase2004Bioorganic & medicinal chemistry letters, Apr-05, Volume: 14, Issue:7
Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium.
AID55820Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii1995Journal of medicinal chemistry, May-12, Volume: 38, Issue:10
6-substituted 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID57628Concentration required to inhibit the Pneumocystis carinii Dihydrofolate reductase by 50% was determined; Range: 9.0-172004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID232632Ratio of inhibitory activity against dihydrofolate reductase of rat liver to Toxoplasma gondii2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
AID55856Inhibitory activity against Pneumocystis. carinii DHFR*2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID229685Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
2,4-Diamino-5-chloroquinazoline analogues of trimetrexate and piritrexim: synthesis and antifolate activity.
AID55851Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID55859Inhibition of dihydrofolate reductase in pneumocystis carinii.1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
AID1198821Inhibition of Pneumocystis carinii DHFR by spectrophotometric assay2015European journal of medicinal chemistry, May-05, Volume: 95Recent advances in the chemistry and biology of pyridopyrimidines.
AID56186Inhibitory activity against Dihydrohydrofolate reductase(DHFR) of Toxoplasma gondii2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID235379Selectivity ratio was measured as IC50 of rlDHFR/IC50 pcDHFR1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID233114Ratio of IC50 against rat liver DHFR and Pneumocystis carinii DHFR (IC50rl/IC50pc)1995Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12
Novel 2,4-diamino-5-substituted-pyrrolo[2,3-d]pyrimidines as classical and nonclassical antifolate inhibitors of dihydrofolate reductases.
AID138419Effect on Pneumocystis carinii pneumonia in SCID mice in presence of leucovorin1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID23701Partition coefficient (logD) (0.1 N NaOH)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID235672Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Toxoplasma gondii DHFR; Range: 0.63-0.972004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID390567Inhibition of Pneumocystis carinii dihydrofolate reductase2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID55683In vitro inhibition of Pneumocystis carinii (Pc) dihydrofolate reductase.2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID233285Selectivity ratio is IC50 of rat liver DHFR to that of Pneumocystis carinii DHFR1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID235299Ratio of DHFR inhibition of rat liver to that of Pneumocystis carinii2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.
AID57976Inhibitory activity against rat DHFR*2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID55835Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii. (high potency)1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID57969Inhibitory activity against rat liver dihydrofolate reductase.1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii.
AID1591497Inhibition of recombinant human DHFR assessed as reduction in consumption of NADPH using 9 uM DHFA as substrate2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
Development of substituted pyrido[3,2-d]pyrimidines as potent and selective dihydrofolate reductase inhibitors for pneumocystis pneumonia infection.
AID57965Inhibitory activity against Dihydrofolate reductase from rat liver was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID55832Inhibitory activity against Pneumocystis carinii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID747612Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID57961Inhibitory activity against dihydrofolate reductase (DHFR) from rat liver1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
AID139777Number of mice infected to that of total number of mice (11/11)1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID55838Inhibitory concentration against Dihydrofolate reductase from Pneumocystis carinii (pc)1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
Synthesis and dihydrofolate reductase inhibitory activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates.
AID56314Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii was evaluated using 90 uM dihydrofolic acid as substrate1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
AID154143Cytotoxic activity was evaluated against P388D1 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID235661Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Pneumocystis carinii DHFR; Range: 0.17-0.422004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID747607Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID56317Inhibitory activity against Toxoplasma gondii Dihydrofolate reductase1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID78403Cytotoxic Activity was evaluated against H460 tumor cells1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
AID57811Inhibition of rat liver dihydrofolate reductase1997Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19
Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
AID55724Inhibitory activity against dihydrofolate reductase in mammalians. (high potency)1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID244388Selectivity index measured as IC50(Rat)/IC50(Mycobacterium avium)2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1995Journal of medicinal chemistry, Mar-03, Volume: 38, Issue:5
2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii.
AID1797706Determination of IC50 from Article 10.1021/jm0581718: \\Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitutio2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
AID493017Wombat Data for BeliefDocking2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (20.83)18.7374
1990's63 (52.50)18.2507
2000's24 (20.00)29.6817
2010's8 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.78 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (16.94%)5.53%
Reviews9 (7.26%)6.00%
Case Studies4 (3.23%)4.05%
Observational0 (0.00%)0.25%
Other90 (72.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM [NCT00002914]Phase 240 participants (Anticipated)Interventional1997-07-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]